



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

VTX-27

Cat. No.:	HY-112782
CAS No.:	1321924-70-2
Molecular Formula:	C ₂₀ H ₂₄ ClFN ₆ O
Molecular Weight:	418.9
Target:	PKC
Pathway:	Epigenetics; TGF-beta/Smad
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (298.40 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Concentration Mass	1 mg	5 mg	10 mg
		1 mM	2.3872 mL	11.9360 mL	23.8720 mL
		5 mM	0.4774 mL	2.3872 mL	4.7744 mL
		10 mM	0.2387 mL	1.1936 mL	2.3872 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.97 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.97 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil				
	Solubility: ≥ 2.08 mg/mL (4.97 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	VTX-27 is a selective protein kinase C θ (PKC θ) inhibitor, with K _i s of 0.08 nM and 16 nM for PKC θ and PKC δ.		
IC ₅₀ & Target	PKCθ 0.08 nM (K_i)	PKCδ 16 nM (K_i)	PKCα 356 nM (K_i)
In Vitro	VTX-27 (Compound 27) possesses excellent overall characteristics. Good selectivity of VTX-27 is also seen against other PKC family members, particularly classical isoforms (>1000-fold except PKCβ I, 200-fold) and atypical isoforms (>10000-fold). As		

	anticipated, attaining selectivity over the more closely related novel PKC family members is more challenging, with a good 200-fold being achieved over PKC δ^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	VTX-27 shows the best PK profile with a low clearance ($7 \text{ mL min}^{-1} \text{ kg}^{-1}$), long half-life (4.7 h), and good oral bioavailability (65%). A single dose of VTX-27 is administered orally at 6.25, 12.5, 25, and 50 mg/kg (e.g., at 25 mg/kg C_{max} concentration 700 ng/mL) and demonstrates potent dose dependent inhibition of IL-2 production^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Jimenez JM, et al. Design and optimization of selective protein kinase C θ (PKC θ) inhibitors for the treatment of autoimmune diseases. J Med Chem. 2013 Mar 14;56(5):1799-810.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA